US 2012/0059049 A1Published application

Bone morphogenic proteins (bmp), bmp receptors and bmp binding proteins and their use in the diagnosis and treatment of glaucoma

AssigneesNorth Texas Health Sciences Center, University of, Novartis AG

InventorsAbbot F. CLARK, Robert J. WORDINGER

Life of this patent

Estimating the term…

Abstract

The present invention provides methods and kits for diagnosing and treating glaucoma.

Claims1

Dependent claims

A method for treating glaucoma comprising administering to a patient in need thereof a composition comprising a gremlin antagonist, wherein the gremlin antagonist is an oligonueleotide.

Dependencies are inferred from the claim text.

Facts

Application: 13/281,816Filed 26 Oct 2011
Priority: 31 Oct 2001
Published: 8 Mar 2012
Term ends: Not estimatedThe source records don’t support an estimate.

Classification13 codes

G01N 33/5023
For testing non-proliferative effects: on expression patterns
A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…
A61P 27/00
Drugs for disorders of the senses
A61P 27/06
Ophthalmic agents: antiglaucoma agents or miotics

Family

Application60/334,852Us provisional application · filed 31 Oct 2001
Application10/286,152Continuation · filed 31 Oct 2002
Application12/106,653Division · filed 21 Apr 2008
Application12/766,056Continuation · filed 23 Apr 2010
Application13/281,816Continuation
Application12/766,056Division
Application12/106,653Continuation
US 2003/0134308 A1Published application
US 2008/0194515 A1Published application
US 2010/0204086 A1Published application
US 7,405,192 B2Related patent
US 7,744,873 B2Related patent
US 8,063,013 B2Related patent
US 8,389,496 B2Related patent
US 2012/0059049 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key

patentgrep

Loading patent…

Facts

Application

13/281,816Filed 26 Oct 2011

Priority

31 Oct 2001

Published

8 Mar 2012

Term ends

Not estimatedThe source records don’t support an estimate.

Classification13 codes

G01N 33/5023
For testing non-proliferative effects: on expression patterns
A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…
A61P 27/00
Drugs for disorders of the senses
A61P 27/06
Ophthalmic agents: antiglaucoma agents or miotics

Family

Application60/334,852Us provisional application · filed 31 Oct 2001

Application10/286,152Continuation · filed 31 Oct 2002

Application12/106,653Division · filed 21 Apr 2008

Application12/766,056Continuation · filed 23 Apr 2010

Application13/281,816Continuation

Application12/766,056Division

Application12/106,653Continuation

US 2003/0134308 A1Published application

US 2008/0194515 A1Published application

US 2010/0204086 A1Published application

US 7,405,192 B2Related patent

US 7,744,873 B2Related patent

US 8,063,013 B2Related patent

US 8,389,496 B2Related patent

US 2012/0059049 A1This patent

From the US filing history. Foreign family members aren’t listed.